Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Salar Silvestre, Antonio
• dc.contributor.author Jiménez-Ubieto, Ana
• dc.contributor.author Lahuerta, Juan José
• dc.contributor.author GELTAMO Group
• dc.date.accessioned 2020-01-23T07:31:11Z
• dc.date.available 2020-01-23T07:31:11Z
• dc.date.issued 2019
• dc.description.abstract Objective/background: Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT. We explored whether ASCT is also an effective option in the pre-rituximab era-that is, in patients treated in induction and rescued only with chemotherapy. Methods: ETF was defined as relapse/progression within 2 years of starting first-line therapy. We identified two groups: the ETF cohort (n = 87) and the non-ETF cohort (n = 47 patients receiving ASCT but not experiencing ETF following first-line therapy). Results: There was a significant difference in 5-year progression-free survival between the ETF and non-ETF cohorts (43% vs. 57%, respectively; p = .048). Nevertheless, in patients with ETF with an interval from first relapse after primary treatment to ASCT of <1 year, no differences were observed in 5-year progression-free survival (48% vs. 66%, respectively; p = .44) or in 5-year OS (69% vs. 77%, p = .4). Patients in the ETF cohort transplanted in complete remission showed a plateau in the OS curves, at 56%, beyond 13.7 years of follow-up. Conclusion: ASCT may be a curative option for ETF in patients who respond to rescue chemotherapy, without the need for immunotherapy or other therapies, and should be considered as an early consolidation, especially in patients with difficult access to rituximab.
• dc.format.mimetype application/pdf
• dc.identifier.citation Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT. Et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):194-203. DOI 10.1016/j.hemonc.2019.06.001
• dc.identifier.doi http://dx.doi.org/10.1016/j.hemonc.2019.06.001
• dc.identifier.issn 1658-3876
• dc.identifier.uri http://hdl.handle.net/10230/43391
• dc.language.iso eng
• dc.publisher Elsevier
• dc.rights 1658-3876/c2019 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Autologous stem cell transplantation
• dc.subject.keyword Early relapse
• dc.subject.keyword Follicular lymphoma
• dc.subject.keyword Survival
• dc.subject.keyword Chemotherapy
• dc.title Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion